Literature DB >> 16528143

Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder.

Eric Hollander1, Bernardo Dell'Osso.   

Abstract

We report a case of treatment-resistant obsessive-compulsive disorder (OCD) that was successfully treated with a pharmacological augmentation of topiramate plus paroxetine. The patient, a 45-year-old woman, was on a stable dose of paroxetine (40 mg/day) when she was started on topiramate (up to 150 mg/day). After 9 weeks of this treatment, her clinical condition remarkably improved, as indicated by a significant decrease of the evaluation scales (Yale-Brown Obsessive-Compulsive Scale and Clinical Global Impression Scale). Our case suggests that topiramate might be beneficial in augmentation with selective serotonin reuptake inhibitors in patients with treatment-resistant OCD, although further investigations are warranted to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528143     DOI: 10.1097/01.yic.0000199453.54799.cc

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  20 in total

1.  High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

Authors:  W Louis Cleveland; Robert L DeLaPaz; Rashid A Fawwaz; Roger S Challop
Journal:  Neural Plast       Date:  2010-02-18       Impact factor: 3.599

Review 2.  Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments.

Authors:  Leonardo F Fontenelle; Sanne Oostermeijer; Ben J Harrison; Christos Pantelis; Murat Yücel
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 3.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

Review 4.  The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder.

Authors:  Ke Wu; Gregory L Hanna; David R Rosenberg; Paul D Arnold
Journal:  Pharmacol Biochem Behav       Date:  2011-10-15       Impact factor: 3.533

Review 5.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

6.  THE USE OF GLUTAMATE MODULATING DRUGS IN OBSESSIVE COMPULSIVE DISORDER.

Authors:  Frank P MacMaster; David R Rosenberg
Journal:  Child Adolesc Psychopharmacol News       Date:  2010-12

7.  Effect of topiramate on acid-base balance: extent, mechanism and effects.

Authors:  Nasir Mirza; Anthony G Marson; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

8.  Effects of mood stabilizers on marble-burying behavior in mice: involvement of GABAergic system.

Authors:  Nobuaki Egashira; Moe Abe; Atsunori Shirakawa; Tomiko Niki; Kenichi Mishima; Katsunori Iwasaki; Ryozo Oishi; Michihiro Fujiwara
Journal:  Psychopharmacology (Berl)       Date:  2012-10-21       Impact factor: 4.530

Review 9.  Translational neuroimaging research in pediatric obsessive-compulsive disorder.

Authors:  Frank P MacMaster
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

10.  Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder.

Authors:  Jonathan T Ting; Guoping Feng
Journal:  Curr Chem Genomics       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.